VibroSense Dynamics AB

And a warm welcome to today's presentation of Arbicens Dynamics Part 1, which will be published this morning. The company has been in business for a year, which means that we are running from the 1st of July to the 30th of June. And today's report covers the 1st of July to the 30th of September this year. My name is Tony Speidel. I am CTO and also a member of the company. And today I also have with me our new CEO, Tarek Cengiz, who will present the report. And with those words, I'll hand it over to Tarek, please.

Hi, my name is Tarek Cengiz and I'm the CEO of Vipersense Dynamics. I'm the new CEO and have been here since September 16th, 2004. Before I start the part-time report, I'm going to make a presentation about myself. I'm a student at Röntgensjuksköterska and have a master's degree in nuclear medicine. I've worked at a clinic and then decided to work in the industry. And so I have done the last 11 years. I started my career at a pharmaceutical company called Manicure Pharmaceuticals. And then I have continued to work at GE Healthcare and then at smaller and medium-sized Swedish companies. I have finally worked with OEMs and distributors for the last five years globally, both in Europe, the Middle East, the USA, Canada and Asia. And I'm super excited and very happy to be a part of Vipersense Dynamics and look forward to my time here at Vipersense Dynamics. With that said, I would like to go in and start presenting part of the Q1 report. I would like to welcome everyone to this presentation. If we look at the total revenue, we had a net revenue of about SEK 430,000 and a revenue of SEK minus SEK 1.2 million. We had a lower revenue in Q1 compared to the previous year during the same period, and this loss of revenue is largely explained by the fact that we simply had lower activity during the first quarter, and we also had reduced sales and outsourcing. Our moving costs have dropped by about 22%. This is due to the fact that we have had lower patent and marketing costs compared to the previous year. During the first quarter, we have continued to work with regulatory approvals in China. A dialogue is being held between our partner UN Care and NMPA. Vi har tidigare kommunicerat ut att vi har ett preliminärt godkännande under april 2025. Vi har också själva täta dialoger och återkommande möten med UMP för att följa den här regulatoriska godkännandeprocessen på nära håll. Under första kvartalet så har vi också fått en intention to grant vad gäller patentansökan i EU som avser hudtemperaturmätning trådlöst före och under en undersökning. Kanske inte under första kvartalet men precis därefter så har vi också kommunicerat ut att utvärdering av Vibrosense Mitri 2 på Diabeteskliniken vid Sten & Diabetescenter Odense i Danmark. It is done and they have decided not to implement Vibrosense Mynt 2 anymore. A short comment regarding this evaluation is that they have evaluated our equipment, our method and compared it to the methods that the clinic uses today. Vibrosense has not been a part of this evaluation but we have received the results of this evaluation and when we We have had a dialogue and pointed out that the comparison method used by the clinic may not have been done in a correct way. We have had a dialogue with the diabetes clinic and pointed out that there have been errors in the comparison method. In summary, we can say that the evaluation that the clinic has done absolutely does not show in any way the performance of Vagrasense Mitre 2 and how it can be used and implemented in the clinical workflow. It has been educational for us as well, of course, that we have learned that when we prepare this type of and when the clinic starts, we will have a protocol that describes the comparisons and how it should be done and which methods should be used. As I said, we measure in different ways and we show different results and then it is important to compare apple to apple so that there are no wrong results at the end. As you also know, Vibrosense Meter has a broad use area. We have three segments that we work in today. It is its hand-to-hand vibration syndrome, diabetes and oncology. In HAVS, we will continue to work to establish new customers, company health care, with direct distribution as we have done before. We will also investigate the opportunities in the UK, where we know that The regulatory aspect of HAVS and how you work with HAVS in the UK can be very different from the other European countries. And you take this very seriously in the UK. So we are also investigating the possibilities and the market in the UK. As for diabetes and diabetes caused by neuropathy, nerve damage in the feet, we have a market transition. We are looking at to find OEM manufacturers and distributors to expand within this segment. We have ongoing projects, both in Germany and the UK, with clinics. We will also participate in Diabetes Hälftagång in Hannover in November. where we will be exhibitors, meeting researchers, clinicians and other companies that are active in diabetes. We will also be at the World Diabetes Talk in Malmö, where our CTO and R&D manager Toni will present the use of our equipment in diabetes neuropathy. We will also host the World Diabetes Day in Malmö, where participants will also be able to get a demonstration and a presentation of the equipment and be able to test it. Oncology is a very large area, and we know that cell poison-inducing nerve damage is a very well-known problem. Vi har ett pågande projekt just inom detta med sjukhus inom CIPN, alltså cellgiftsinducerade nervskador, där vi försöker titta på det kliniska arbetsflödet, hur undersökningen både som en baseline innan man börjar få cellgifter och under pågående behandling. För så som det är idag vad gäller cellgifter så får ju patienter It is well known that patients get nerve injuries and suffer from it, but it is very subjective today. So the clinics need more objective and quantitative data to see how they are affected by measuring this. And in this way, maybe adjust the dosage according to the advocate's treatment of cancer. Vi söker också samarbetspartners inom industrin, just inom CIP, där vi vet att det finns företag som arbetar aktivt för att antingen behandla eller förebygga just PFR-närvslådor vid säljsbehandlingar. So we will work in parallel with these three segments. In certain periods of time, we may focus on one segment more than the other, but we will be active and we will not leave any segment unattended. Our business model, which we have also previously communicated, we want to grow through partnerships, we want to grow through OEM manufacturers and distributors. We really want to find these manufacturers and distributors who have the relations, the network and the product portfolio within the same segment as we have. So the commercial focus will be strong. We have also changed our pricing model so that it will be more attractive for end customers. There will also be an adjustment to the distributors when we start to find partners in diabetes or cancer or oncology and find partners as distributors or OEM manufacturers. We also want them to be able to be flexible with the prices when it comes to purchases and equipment. We also have a research that takes place to look at the market, to look at the geographical expansion. We are MDR class 1, so we also want to look at the countries and look at the markets we can today. börja marknadsföra och sälja vår produkt och se vilka länder och vilka regioner vi har den största lönsamheten. Before the preparations for the market in China, the regulatory process is underway. In parallel with this, we also want to start working and preparing for the market and sales in China. This is something that we will work on in parallel with UMCare. with their marketing plan to start these preparations. Because when the regulatory approval in China is complete, we want to start the sales and marketing process immediately afterwards. And with that said, I would like to say thank you and move on to questions and thoughts that you have.

Thank you, Tarik. That was short and concise. Good. We are now ready to ask questions. There is a chat icon down below that you can type in. Let's see if we have received any questions. Here comes a question. I see it here. Thank you. Can you maybe answer it? What do you think about the latest article published about vibration damage on construction workers?